To main content

ICUE – Illuminating the Path to Cure Endometriosis

Endometriosis affects approximately 10% of women of reproductive age, yet treatment options remain limited. ICUE combines biotechnology, nanotechnology, and photonics to develop new tools that may enable improved diagnostics, more precise surgery, and future targeted treatments for the disease.

Contact person

Endometriosis affects approximately one in ten women of reproductive age and is among the most common chronic diseases affecting women. The condition occurs when tissue resembling the lining of the uterus grows outside the uterine cavity, causing severe pain, fatigue, infertility, and a significantly reduced quality of life. Despite affecting millions of women worldwide, there is still no curative treatment available.

New models for research on endometriosis

ICUE aims to address some of these challenges by developing innovative approaches for understanding, detecting, and treating endometriosis. By combining biotechnology, nanotechnology, photonics, and artificial intelligence, the project will create new tools to advance endometriosis research and care. Researchers will establish advanced laboratory models based on patient-derived cells, including organoids generated from endometriosis tissue and menstrual blood. These models will be used to investigate disease mechanisms and evaluate drugs to identify new treatment opportunities or gain a better understanding of existing therapeutic options.

The project will also explore nanoparticles capable of delivering drugs or imaging agents directly to endometriotic lesions. The goal is to enable more targeted treatments with fewer side effects. In parallel, fluorescent markers and optical imaging technologies will be developed to help surgeons identify and remove diseased tissue more accurately during surgical procedures.

The organoids grown in the laboratory provide new knowledge about disease and treatment.
The organoids grown in the laboratory provide new knowledge about disease and treatment.

Project partners and collaboration

SINTEF coordinates the project and contributes expertise in cell models, drug screening, nanotechnology, and biological data analysis. The work is carried out in close collaboration with clinicians, patient organizations, and research institutions to ensure that the technologies being developed address real-world needs in healthcare and improve outcomes for individuals living with endometriosis.

The project brings together partners from SINTEF, NTNU, Karolinska Institutet, St. Olavs Hospital, Oslo University Hospital, and the Norwegian Endometriosis Association. Together, they aim to generate new knowledge and technologies that can lay the foundation for future advances in endometriosis treatment.

Caption header image: Bjørnar Øvrebø.

Key facts

Project duration

2025 - 2028

Funding

Funded by the Research Council of Norway (353112)

Partners

  • SINTEF (project owner and coordinator)
  • NTNU
  • Karolinska Institutet
  • St. Olavs Hospital
  • Oslo University Hospital
  • Endometrioseforeningen (The Endometriosis Association)

Relevant laboratories and research infrastructure